Annie Bouchard
10Patents
5h-index
9Co-inventors
51Inventor score
Filing activity: Dec 18, 2014 → Nov 5, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10349884B2 | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel | Human Necessities | 15 | Active |
| US10238602B2 | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies | Physics | 15 | Active |
| US10258691B2 | Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies | Physics | 15 | Active |
| US10449193B2 | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies | Physics | 13 | Active |
| US10532045B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | Human Necessities | 6 | Active |
| US10975111B2 | Cardiopathy-reducing phosphodiester lipids | Human Necessities | 2 | Active |
| US11746119B2 | Cardiopathy-reducing phosphodiester lipids | Human Necessities | 0 | Active |
| US11806401B2 | Prevention of drug-induced atrio-ventricular block | Human Necessities | 0 | Active |
| US12004868B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | Human Necessities | 0 | Active |
| US11643424B2 | Cardiopathy-reducing phosphodiester lipids | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.